Cadrenal Therapeutics (CVKD) CEO Quang Pham Sells $51K of Stock

Quang Pham, the Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc. (NasdaqCM: CVKD), sold 12,996 shares of the company on June 12, 2026. The shares were sold at an average price of $3.94, totaling $51,204. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Cadrenal Therapeutics, Inc.

Quang Pham has been actively trading shares of Cadrenal Therapeutics. On June 15, 2026, he sold another 3,666 shares at $3.58 each. Earlier, on June 11, 2026, he sold 1,462 shares at $4.12, and on June 10, 2026, he sold 3,500 shares at $4.21 under a pre-planned trading arrangement.

Other Institutional Activity in Cadrenal Therapeutics

Several institutional investors have also made moves in Cadrenal Therapeutics. Vanguard Capital Management LLC added 45,201 shares, bringing its total to 45,201 shares valued at approximately $231,429. Geode Capital Management, LLC increased its position by 7,098 shares, ending with 21,626 shares worth $110,724. BlackRock, Inc. grew its holdings by 1,974 shares to a total of 5,496 shares, valued at $28,140.

Cadrenal Therapeutics, Inc. Stock Up 211.2%

Shares of Cadrenal Therapeutics, Inc. recently traded at $3.33. The company has a market capitalization of about $10.3 million. The stock's 52-week range is between $3.27 and $14.64. The 50-day moving average is $5.07, and the 200-day moving average is $8.60. With a current ratio of 2.68 and a quick ratio of 2.17, the company's financial position remains stable despite its lack of profitability, reflected in a negative forward P/E ratio.

Analysts Set New Price Targets

On April 7, 2026, HC Wainwright & Co. maintained its 'buy' rating on Cadrenal Therapeutics with a price target of $13. The consensus among analysts is a 'buy' rating, with an average target price of $27.67 based on three analyst opinions.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc. is a biopharmaceutical company headquartered in Ponte Vedra, Florida. It focuses on developing treatments for severe immune and thrombotic conditions. The company's leading product, Tecarfarin, is in a Phase 3 trial for preventing blood clots in patients needing chronic anticoagulation. Cadrenal also works on CAD-1005 and Frunexian, targeting thrombotic disorders and acute hospital settings. Founded in 2022, the company is led by CEO Quang X. Pham.

Bottom Line

Quang Pham's recent share sales reflect his ongoing activity in the market, though not necessarily a negative signal. Cadrenal Therapeutics continues to attract institutional interest, as evidenced by recent moves by major funds. Investors keep a close eye on these developments, keeping in mind that insider transactions are reported after they occur and may not indicate future intentions.